Eurofins Scientific SE
Eurofins Scientific SE (ERFSF) Stock Competitors & Peer Comparison
See (ERFSF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ERFSF | $76.37 | +5.97% | 13.5B | 25.98 | $2.94 | +0.91% |
| LZAGY | $63.35 | -0.58% | 46B | 39.70 | $1.63 | +0.65% |
| WUXAY | $15.19 | -0.07% | 45B | 16.39 | $0.96 | +1.17% |
| LZAGF | $643.90 | -0.98% | 43.8B | 38.42 | $16.26 | +0.38% |
| WUXIF | $13.88 | +0.00% | 41.4B | 14.46 | $0.96 | +1.68% |
| BMXMF | $102.25 | +0.00% | 12.1B | 26.56 | $3.85 | +1.00% |
| SKHHY | $14.07 | -1.09% | 7B | 18.55 | $0.76 | +4.67% |
| SKHCF | $13.30 | +0.00% | 6.6B | 17.97 | $0.74 | +5.48% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
| DSRLF | $67.00 | +0.00% | 3.6B | 20.49 | $3.27 | +2.10% |
Stock Comparison
ERFSF vs LZAGY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, LZAGY has a market cap of 46B. Regarding current trading prices, ERFSF is priced at $76.37, while LZAGY trades at $63.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas LZAGY's P/E ratio is 39.70. In terms of profitability, ERFSF's ROE is +0.12%, compared to LZAGY's ROE of +0.11%. Regarding short-term risk, ERFSF is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check LZAGY's competition here
ERFSF vs WUXAY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, WUXAY has a market cap of 45B. Regarding current trading prices, ERFSF is priced at $76.37, while WUXAY trades at $15.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas WUXAY's P/E ratio is 16.39. In terms of profitability, ERFSF's ROE is +0.12%, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, ERFSF is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check WUXAY's competition here
ERFSF vs LZAGF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, LZAGF has a market cap of 43.8B. Regarding current trading prices, ERFSF is priced at $76.37, while LZAGF trades at $643.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas LZAGF's P/E ratio is 38.42. In terms of profitability, ERFSF's ROE is +0.12%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, ERFSF is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check LZAGF's competition here
ERFSF vs WUXIF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, ERFSF is priced at $76.37, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas WUXIF's P/E ratio is 14.46. In terms of profitability, ERFSF's ROE is +0.12%, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, ERFSF is less volatile compared to WUXIF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check WUXIF's competition here
ERFSF vs BMXMF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BMXMF has a market cap of 12.1B. Regarding current trading prices, ERFSF is priced at $76.37, while BMXMF trades at $102.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BMXMF's P/E ratio is 26.56. In terms of profitability, ERFSF's ROE is +0.12%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, ERFSF is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check BMXMF's competition here
ERFSF vs SKHHY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SKHHY has a market cap of 7B. Regarding current trading prices, ERFSF is priced at $76.37, while SKHHY trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SKHHY's P/E ratio is 18.55. In terms of profitability, ERFSF's ROE is +0.12%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, ERFSF is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check SKHHY's competition here
ERFSF vs SKHCF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SKHCF has a market cap of 6.6B. Regarding current trading prices, ERFSF is priced at $76.37, while SKHCF trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SKHCF's P/E ratio is 17.97. In terms of profitability, ERFSF's ROE is +0.12%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, ERFSF is more volatile compared to SKHCF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check SKHCF's competition here
ERFSF vs HNGZY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, ERFSF is priced at $76.37, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, ERFSF's ROE is +0.12%, compared to HNGZY's ROE of +0.03%. Regarding short-term risk, ERFSF is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check HNGZY's competition here
ERFSF vs DSRLF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, DSRLF has a market cap of 3.6B. Regarding current trading prices, ERFSF is priced at $76.37, while DSRLF trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas DSRLF's P/E ratio is 20.49. In terms of profitability, ERFSF's ROE is +0.12%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, ERFSF is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check DSRLF's competition here
ERFSF vs VIMGF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, ERFSF is priced at $76.37, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, ERFSF's ROE is +0.12%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, ERFSF is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check VIMGF's competition here
ERFSF vs GNTLF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, ERFSF is priced at $76.37, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, ERFSF's ROE is +0.12%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, ERFSF is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check GNTLF's competition here
ERFSF vs MRCHF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MRCHF has a market cap of 1.3B. Regarding current trading prices, ERFSF is priced at $76.37, while MRCHF trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MRCHF's P/E ratio is 70.97. In terms of profitability, ERFSF's ROE is +0.12%, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, ERFSF is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check MRCHF's competition here
ERFSF vs IDGXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, ERFSF is priced at $76.37, while IDGXF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IDGXF's P/E ratio is 21.33. In terms of profitability, ERFSF's ROE is +0.12%, compared to IDGXF's ROE of +0.38%. Regarding short-term risk, ERFSF is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IDGXF's competition here
ERFSF vs EDTXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, EDTXF has a market cap of 289.1M. Regarding current trading prices, ERFSF is priced at $76.37, while EDTXF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas EDTXF's P/E ratio is -8.33. In terms of profitability, ERFSF's ROE is +0.12%, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, ERFSF is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check EDTXF's competition here
ERFSF vs AMCY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, ERFSF is priced at $76.37, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas AMCY's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to AMCY's ROE of N/A. Regarding short-term risk, ERFSF is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check AMCY's competition here
ERFSF vs NNGRF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, ERFSF is priced at $76.37, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, ERFSF's ROE is +0.12%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, ERFSF is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check NNGRF's competition here
ERFSF vs DIUXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, ERFSF is priced at $76.37, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, ERFSF's ROE is +0.12%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, ERFSF is less volatile compared to DIUXF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check DIUXF's competition here
ERFSF vs CORBF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, CORBF has a market cap of 140.6M. Regarding current trading prices, ERFSF is priced at $76.37, while CORBF trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas CORBF's P/E ratio is 3.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, ERFSF is less volatile compared to CORBF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check CORBF's competition here
ERFSF vs LDXHF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, LDXHF has a market cap of 128.8M. Regarding current trading prices, ERFSF is priced at $76.37, while LDXHF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas LDXHF's P/E ratio is -16.15. In terms of profitability, ERFSF's ROE is +0.12%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, ERFSF is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check LDXHF's competition here
ERFSF vs THOXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, ERFSF is priced at $76.37, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas THOXF's P/E ratio is -7.45. In terms of profitability, ERFSF's ROE is +0.12%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, ERFSF is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check THOXF's competition here
ERFSF vs TIHE Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, ERFSF is priced at $76.37, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas TIHE's P/E ratio is 0.32. In terms of profitability, ERFSF's ROE is +0.12%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, ERFSF is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check TIHE's competition here
ERFSF vs PFGTF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, ERFSF is priced at $76.37, while PFGTF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, ERFSF's ROE is +0.12%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, ERFSF is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check PFGTF's competition here
ERFSF vs BIOGF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, ERFSF is priced at $76.37, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, ERFSF's ROE is +0.12%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, ERFSF is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check BIOGF's competition here
ERFSF vs PCNEF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, ERFSF is priced at $76.37, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, ERFSF's ROE is +0.12%, compared to PCNEF's ROE of -0.06%. Regarding short-term risk, ERFSF is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check PCNEF's competition here
ERFSF vs BMKDF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BMKDF has a market cap of 45.9M. Regarding current trading prices, ERFSF is priced at $76.37, while BMKDF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BMKDF's P/E ratio is -43.68. In terms of profitability, ERFSF's ROE is +0.12%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, ERFSF is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check BMKDF's competition here
ERFSF vs BIOQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, ERFSF is priced at $76.37, while BIOQ trades at $37.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, ERFSF's ROE is +0.12%, compared to BIOQ's ROE of +0.01%. Regarding short-term risk, ERFSF is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check BIOQ's competition here
ERFSF vs SNANF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SNANF has a market cap of 27M. Regarding current trading prices, ERFSF is priced at $76.37, while SNANF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SNANF's P/E ratio is -11.80. In terms of profitability, ERFSF's ROE is +0.12%, compared to SNANF's ROE of -4.34%. Regarding short-term risk, ERFSF is less volatile compared to SNANF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check SNANF's competition here
ERFSF vs ANPCY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, ERFSF is priced at $76.37, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, ERFSF's ROE is +0.12%, compared to ANPCY's ROE of -1.05%. Regarding short-term risk, ERFSF is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check ANPCY's competition here
ERFSF vs PCHM Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, ERFSF is priced at $76.37, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas PCHM's P/E ratio is -0.02. In terms of profitability, ERFSF's ROE is +0.12%, compared to PCHM's ROE of +0.36%. Regarding short-term risk, ERFSF is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check PCHM's competition here
ERFSF vs VILGF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, ERFSF is priced at $76.37, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas VILGF's P/E ratio is -0.30. In terms of profitability, ERFSF's ROE is +0.12%, compared to VILGF's ROE of N/A. Regarding short-term risk, ERFSF is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check VILGF's competition here
ERFSF vs CLIFF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, ERFSF is priced at $76.37, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, ERFSF's ROE is +0.12%, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, ERFSF is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check CLIFF's competition here
ERFSF vs LDDD Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, ERFSF is priced at $76.37, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas LDDD's P/E ratio is -51.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to LDDD's ROE of -0.28%. Regarding short-term risk, ERFSF is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check LDDD's competition here
ERFSF vs ABDXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, ERFSF is priced at $76.37, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, ERFSF's ROE is +0.12%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, ERFSF is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check ABDXF's competition here
ERFSF vs IZOZF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IZOZF has a market cap of 10.9M. Regarding current trading prices, ERFSF is priced at $76.37, while IZOZF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IZOZF's P/E ratio is -8.04. In terms of profitability, ERFSF's ROE is +0.12%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, ERFSF is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IZOZF's competition here
ERFSF vs MXDHF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, ERFSF is priced at $76.37, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, ERFSF's ROE is +0.12%, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, ERFSF is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check MXDHF's competition here
ERFSF vs IDXG Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IDXG has a market cap of 8.1M. Regarding current trading prices, ERFSF is priced at $76.37, while IDXG trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IDXG's P/E ratio is -2.79. In terms of profitability, ERFSF's ROE is +0.12%, compared to IDXG's ROE of +4.85%. Regarding short-term risk, ERFSF is more volatile compared to IDXG. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check IDXG's competition here
ERFSF vs JMPHF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, ERFSF is priced at $76.37, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, ERFSF's ROE is +0.12%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, ERFSF is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check JMPHF's competition here
ERFSF vs IMMVF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, ERFSF is priced at $76.37, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, ERFSF's ROE is +0.12%, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, ERFSF is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IMMVF's competition here
ERFSF vs SQIDF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, ERFSF is priced at $76.37, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, ERFSF's ROE is +0.12%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, ERFSF is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check SQIDF's competition here
ERFSF vs PMSNF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, PMSNF has a market cap of 5.3M. Regarding current trading prices, ERFSF is priced at $76.37, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to PMSNF's ROE of +0.44%. Regarding short-term risk, ERFSF is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check PMSNF's competition here
ERFSF vs AVCRF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, AVCRF has a market cap of 4.6M. Regarding current trading prices, ERFSF is priced at $76.37, while AVCRF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas AVCRF's P/E ratio is -4.51. In terms of profitability, ERFSF's ROE is +0.12%, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, ERFSF is more volatile compared to AVCRF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check AVCRF's competition here
ERFSF vs VRCDF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, ERFSF is priced at $76.37, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, ERFSF's ROE is +0.12%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, ERFSF is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check VRCDF's competition here
ERFSF vs RNVA Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, ERFSF is priced at $76.37, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas RNVA's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, ERFSF is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check RNVA's competition here
ERFSF vs ANPCF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ANPCF has a market cap of 4.2M. Regarding current trading prices, ERFSF is priced at $76.37, while ANPCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ANPCF's P/E ratio is -0.21. In terms of profitability, ERFSF's ROE is +0.12%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, ERFSF is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check ANPCF's competition here
ERFSF vs ICBU Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ICBU has a market cap of 3.9M. Regarding current trading prices, ERFSF is priced at $76.37, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ICBU's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to ICBU's ROE of +0.20%. Regarding short-term risk, ERFSF is more volatile compared to ICBU. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check ICBU's competition here
ERFSF vs TDSGF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, TDSGF has a market cap of 3.6M. Regarding current trading prices, ERFSF is priced at $76.37, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas TDSGF's P/E ratio is -3.60. In terms of profitability, ERFSF's ROE is +0.12%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, ERFSF is less volatile compared to TDSGF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check TDSGF's competition here
ERFSF vs IBXXF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IBXXF has a market cap of 2.5M. Regarding current trading prices, ERFSF is priced at $76.37, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IBXXF's P/E ratio is -1.12. In terms of profitability, ERFSF's ROE is +0.12%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, ERFSF is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IBXXF's competition here
ERFSF vs IVRO Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IVRO has a market cap of 1.9M. Regarding current trading prices, ERFSF is priced at $76.37, while IVRO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IVRO's P/E ratio is -0.78. In terms of profitability, ERFSF's ROE is +0.12%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, ERFSF is less volatile compared to IVRO. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IVRO's competition here
ERFSF vs CHHL Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, ERFSF is priced at $76.37, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas CHHL's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, ERFSF is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check CHHL's competition here
ERFSF vs SLDX Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, ERFSF is priced at $76.37, while SLDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SLDX's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to SLDX's ROE of +0.06%. Regarding short-term risk, ERFSF is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check SLDX's competition here
ERFSF vs DIGP Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, ERFSF is priced at $76.37, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas DIGP's P/E ratio is -1.04. In terms of profitability, ERFSF's ROE is +0.12%, compared to DIGP's ROE of +1.19%. Regarding short-term risk, ERFSF is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check DIGP's competition here
ERFSF vs EPGNF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, ERFSF is priced at $76.37, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, ERFSF's ROE is +0.12%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, ERFSF is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check EPGNF's competition here
ERFSF vs RSHN Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, ERFSF is priced at $76.37, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas RSHN's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, ERFSF is more volatile compared to RSHN. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check RSHN's competition here
ERFSF vs IDTA Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IDTA has a market cap of 708K. Regarding current trading prices, ERFSF is priced at $76.37, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IDTA's P/E ratio is 1.75. In terms of profitability, ERFSF's ROE is +0.12%, compared to IDTA's ROE of -0.09%. Regarding short-term risk, ERFSF is less volatile compared to IDTA. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IDTA's competition here
ERFSF vs SZLSF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, ERFSF is priced at $76.37, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, ERFSF's ROE is +0.12%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, ERFSF is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check SZLSF's competition here
ERFSF vs SCRSF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, ERFSF is priced at $76.37, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, ERFSF's ROE is +0.12%, compared to SCRSF's ROE of +1.14%. Regarding short-term risk, ERFSF is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check SCRSF's competition here
ERFSF vs NSTM Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, ERFSF is priced at $76.37, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas NSTM's P/E ratio is 0.20. In terms of profitability, ERFSF's ROE is +0.12%, compared to NSTM's ROE of -0.83%. Regarding short-term risk, ERFSF is more volatile compared to NSTM. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check NSTM's competition here
ERFSF vs MBGNF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, ERFSF is priced at $76.37, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, ERFSF's ROE is +0.12%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, ERFSF is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check MBGNF's competition here
ERFSF vs NVTAQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, ERFSF is priced at $76.37, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, ERFSF is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check NVTAQ's competition here
ERFSF vs ARYC Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, ERFSF is priced at $76.37, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ARYC's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, ERFSF is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check ARYC's competition here
ERFSF vs HCLC Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, ERFSF is priced at $76.37, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas HCLC's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, ERFSF is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check HCLC's competition here
ERFSF vs MEDD Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, ERFSF is priced at $76.37, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MEDD's P/E ratio is -0.02. In terms of profitability, ERFSF's ROE is +0.12%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, ERFSF is less volatile compared to MEDD. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check MEDD's competition here
ERFSF vs IHTI Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, ERFSF is priced at $76.37, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas IHTI's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, ERFSF is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check IHTI's competition here
ERFSF vs TOMDF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, ERFSF is priced at $76.37, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas TOMDF's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, ERFSF is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check TOMDF's competition here
ERFSF vs CGNH Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, ERFSF is priced at $76.37, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas CGNH's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, ERFSF is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check CGNH's competition here
ERFSF vs ABMC Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, ERFSF is priced at $76.37, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ABMC's P/E ratio is 0.01. In terms of profitability, ERFSF's ROE is +0.12%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, ERFSF is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check ABMC's competition here
ERFSF vs CYPS Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, ERFSF is priced at $76.37, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas CYPS's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to CYPS's ROE of N/A. Regarding short-term risk, ERFSF is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check CYPS's competition here
ERFSF vs RGDXQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, ERFSF is priced at $76.37, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, ERFSF is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check RGDXQ's competition here
ERFSF vs DMTKQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, ERFSF is priced at $76.37, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, ERFSF is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check DMTKQ's competition here
ERFSF vs MEDVF Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, ERFSF is priced at $76.37, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MEDVF's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, ERFSF is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check MEDVF's competition here
ERFSF vs GWHP Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, ERFSF is priced at $76.37, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas GWHP's P/E ratio is -0.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, ERFSF is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check GWHP's competition here
ERFSF vs ROSGQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, ERFSF is priced at $76.37, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, ERFSF is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check ROSGQ's competition here
ERFSF vs BIOCQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, ERFSF is priced at $76.37, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, ERFSF is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check BIOCQ's competition here
ERFSF vs HTGMQ Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, ERFSF is priced at $76.37, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, ERFSF is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check HTGMQ's competition here
ERFSF vs OPGX Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, OPGX has a market cap of 17. Regarding current trading prices, ERFSF is priced at $76.37, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas OPGX's P/E ratio is -0.00. In terms of profitability, ERFSF's ROE is +0.12%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, ERFSF is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for ERFSF.Check OPGX's competition here
ERFSF vs EPGNY Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, ERFSF is priced at $76.37, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, ERFSF's ROE is +0.12%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, ERFSF is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check EPGNY's competition here
ERFSF vs AGHC Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, AGHC has a market cap of 0. Regarding current trading prices, ERFSF is priced at $76.37, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas AGHC's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, ERFSF is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check AGHC's competition here
ERFSF vs BGNX Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, BGNX has a market cap of 0. Regarding current trading prices, ERFSF is priced at $76.37, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas BGNX's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to BGNX's ROE of N/A. Regarding short-term risk, ERFSF is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check BGNX's competition here
ERFSF vs MRPS Comparison April 2026
ERFSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERFSF stands at 13.5B. In comparison, MRPS has a market cap of 0. Regarding current trading prices, ERFSF is priced at $76.37, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERFSF currently has a P/E ratio of 25.98, whereas MRPS's P/E ratio is N/A. In terms of profitability, ERFSF's ROE is +0.12%, compared to MRPS's ROE of N/A. Regarding short-term risk, ERFSF is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for ERFSF.Check MRPS's competition here